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Abstract: Serum proteomic analysis can be a valuable approach for the discovery of 
protein biomarkers for early detection or monitoring of a disease. In this study, two 
analytical methods were compared for quantification of serum proteins in patients with oral 
cancer. In the first approach, we quantified serum proteins between oral squamous cell 
carcinoma (OSCC) and healthy control subjects by performing in-solution digestion of 
serum proteins, isobaric tags for relative and absolute quantification (iTRAQ) labeling of 
the resulting peptides, strong cation exchange (SCX) fractionation of labeled peptides and 
finally capillary liquid chromatography with tandem mass spectrometry (LC-MS/MS) 
analysis of the peptides. In the second approach, we first separated serum proteins with 
SDS-PAGE. The gel-separated proteins were then digested with trypsin and the resulting 
peptides were labeled with iTRAQ and analyzed with LC-MS/MS for protein quantification. 
A total of 319 serum proteins were quantified with the first proteomic approach whereas  
a total of 281 proteins were quantified by the second proteomic approach. Most of the 
proteins were identified and quantified by both approaches, suggesting that these methods 
are similarly effective for serum proteome analysis. This study provides compelling 
evidence that quantitative serum proteomic analysis of OSCC is a valuable approach for 
identifying differentially expressed proteins in cancer patients’ circulation systems that 
OPEN ACCESS 
Int. J. Mol. Sci. 2014, 15 14387 
 
 
may be used as potential biomarkers for disease detection. Further validation in large oral 
cancer patient populations may lead to a simple and low invasive clinical tool for OSCC 
diagnosis or monitoring. 
Keywords: serum proteomics; oral squamous cell carcinoma; mass spectrometry;  
stable isotope labeling; protein biomarker 
 
1. Introduction 
Oral cancer is a subgroup of head and neck cancer that affects many regions of the oral cavity,  
such as the lips, tongue, salivary glands, and gums. It is considered as the sixth most common cancer, 
accounting for nearly 3% of the total cancer burden and results in 128,000 annual deaths globally [1,2]. 
The most common type of oral cancer is oral squamous cell carcinoma (OSCC), which makes up 90% 
of all oral cancer cases. Patients with OSCC are often diagnosed at a late stage, and there is a high 
recurrence rate after treatment, especially in those with neck lymph node metastasis [3]. Despite 
clinical and treatment advances, the overall 5-year survival rates for oral cancer have remained low 
and stagnant during the past few decades [4,5]. 
Although OSCC is commonly diagnosed through oral examination followed by histopathology and 
computed tomography/positron emission tomography scanning, there has been continuous interest in 
developing serum protein biomarkers to aid the diagnosis of the disease. Tumor antigens are well 
received as promising diagnostic biomarkers for human cancers, including OSCC. A number of studies 
were performed to investigate the clinical utility of tumor antigens, such as carcinoembryonic antigen 
(CEA), CA-50, CA19-9 and squamous cell carcinoma antigen (SCCA), for OSCC detection [6–9]. 
Serum SCCA appeared to be more sensitive than the other tumor antigens and was found to be positive 
in 38.1% and 41.4% of OSCC patients under testing [8,9]. Studies also revealed other potential serum 
protein biomarkers for OSCC, such as CYFRA 21-1 (cytokeratin 19-fragments), tumor polypeptide 
antigen (TPA) and insulin-like growth factor binding protein 3 [10,11]. CYFRA 21-1 has been 
demonstrated as a promising biomarker for other solid tumors, whereas TPA is a serine protease found 
in rapidly growing tissue due to its role in forming intermediate filaments of the cellular cytoskeleton, 
making it a promising candidate for cancer detection. Both CYFRA 21-1 and TPA levels were found 
to be significantly higher in OSCC patients than healthy controls and benign tumor patients, and they 
were both reduced in patients 2–3 weeks after surgical resection of their OSCC lesions [11]. Although 
these potential serum protein biomarkers need to be further validated in large clinical trials, the 
potential of testing serum protein biomarkers as a simple diagnostic tool for oral/head and neck cancer 
has been well demonstrated in the previously published studies.  
The purpose of our study is to demonstrate and compare two proteomics approaches for quantitative 
analysis of serum proteins from OSCC patients. The quantitative proteomic analysis was based on 
isobaric tags for relative and absolute quantification (iTRAQ) and liquid chromatography with tandem 
mass spectrometry (LC-MS/MS). iTRAQ employs a 4-plex or 8-plex set of amine reactive isobaric 
tags to derivatize peptides at the N-terminus and lysine side chains. In MS, the same peptides labeled 
with any of the isotopic tags are indistinguishable (isobaric). Upon fragmentation in MS/MS, signature 
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reporter ions (e.g., m/z from 114–117) are produced, providing quantitative information for  
the peptides originated from different protein samples [12]. Using similar quantitative proteomics 
approaches, we have previously identified serum protein biomarkers for classification of oral cancer 
patients with lymph node metastasis [13] and revealed that the cAMP response element-binding 
protein 1 (CREB1) pathway is activated in oral cancer stem-like cells [14]. In the present study, two 
quantitative proteomics approaches were compared for analysis of serum proteins of oral cancer 
patients and used to identify differentially expressed serum proteins between OSCC and matched 
healthy control subjects that might be used as candidate biomarkers for further validation.  
2. Results and Discussion  
Two analytical methods were compared in this study for the discovery of putative serum protein 
biomarkers of oral cancer. In the first approach, we quantified serum proteins between OSCC and 
healthy control subjects by performing in-solution digestion of serum proteins, iTRAQ labeling of the 
resulting peptides, strong cation exchange (SCX) fractionation of labeled peptides and finally capillary 
LC with MS/MS analysis of the peptides. In the second approach, we first separated serum proteins 
with SDS-PAGE. The gel-separated proteins were then digested with trypsin, and the resulting 
peptides were labeled with iTRAQ and analyzed with LC-MS/MS for protein quantification (Figure 1).  
Figure 1. The workflow for the two proteomic approaches used to quantify serum proteins 
from patients with oral squamous cell carcinoma (OSCC). (A) In the first approach,  
we quantified serum proteins between OSCC and healthy control subjects by performing 
in-solution digestion of serum proteins, isobaric tags for relative and absolute quantification 
(iTRAQ) labeling of the resulting peptides, SCX (strong cation exchange) separation of 
labeled peptides and finally capillary LC with MS/MS analysis of the peptides; and (B) In 
the second approach, we first separated serum proteins with SDS-PAGE. The gel-separated 
proteins were then digested with trypsin and the resulting peptides were labeled with 
iTRAQ and analyzed with LC-MS/MS for protein quantification.  
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Figure 2 illustrates the number of proteins that were quantified by combining iTRAQ with SCX 
pre-fractionation and LC-MS/MS analysis of labeled peptides (Approach 1). In total, 617 (redundant) 
protein IDs were obtained from the LC-MS/MS analysis of five SCX fractions (Figure 2A,B), which 
corresponded to 319 unique proteins. The relative levels of the 319 proteins between OSCC and 
healthy control subjects are shown in Figure 2B. Quantification of these proteins was based on one or 
more iTRAQ-labeled peptides from each protein. A major obstacle to serum proteome analysis is the 
predominance of highly abundant proteins such as albumins, immunoglobulins, alpha-1-antitrypsin, 
haptoglobin, and their isoforms and fragments. Depletion of these proteins in serum samples is desired 
for an in-depth proteomic analysis. Immunoaffinity depletion using multiple affinity removal columns 
is effective because it can simultaneously remove multiple abundant proteins, with minimal carryover 
and high specificity. Immunodepletion can also be performed with columns packed with antibody-coated 
microbeads. In our study, we used the IgY-12 SC spin columns, in which affinity-purified anti-IgY 
antibodies are covalently conjugated through their Fc portion to 60 µm polymeric microbeads, to 
deplete highly abundant serum proteins prior to quantitative MS analysis. This affinity column is 
effective to deplete 90%–99% of 12 abundant serum proteins including albumin, IgG, transferrin, 
fibrinogen, IgA, alpha-2-macroglobulin, IgM, alpha-1-antitrypsin, haptoglobin, alpha-1-acid glycoprotein, 
apolipoprotein A-I, and apolipoprotein A-II. However, there are two remaining issues with this affinity 
depletion approach. First, it removes a good portion, but not all of the highly abundant proteins.  
Most of the 12 abundant proteins were found to be present in the depleted samples, interfering with 
downstream analysis. The amount of remaining high abundant proteins may vary from sample to 
sample. This would affect protein assays of the depleted samples, leading to inaccurate iTRAQ 
quantification. Second, there has been concern regarding whether low-abundance proteins are removed 
along with high-abundance proteins such as albumin and immunoglobulins via non-specific binding.  
A possible approach to address this problem is to disrupt the binding of other serum proteins to  
the carrier proteins albumin/immunoglobulin. For instance, partly denaturing conditions by adding 
5%–20% acetonitrile may disrupt the binding, resulting in an increased number of detected proteins  
in comparison with native conditions [15]. Therefore, in the first approach, we first used 10% 
acetonitrile to break down the binding between proteins, and then we used immunoaffinity depletion 
spin columns to remove the highly abundant proteins from serum samples prior to in-solution digestion 
and iTRAQ labeling. 
We also tested another approach for quantitative analysis of serum proteins by combining SDS-PAGE 
separation of proteins, in-gel digestion and iTRAQ labeling of the resulting peptides, and SCX  
pre-fractionation with LC-MS/MS of iTRAQ-labeled peptides (Approach 2). Using this method,  
281 proteins were quantified, and their relative levels between OSCC and healthy control subjects  
are shown in Figure 3. In the second approach, rather than depleting highly abundant proteins with 
affinity columns, we used SDS-PAGE to separate the serum proteins and relatively low abundant 
protein bands were excised for in-gel tryptic digestion and iTRAQ labeling of the resulting peptides. 
This approach avoided the most abundant proteins at 55–70 kDa (e.g., serum albumin) and ~28 kDa  
(e.g., IgG light chain), but those low abundant proteins around 28 kDa or within 50–70 kDa might be 
lost during the process. Approach 1 represents fractionation at peptide level whereas Approach 2 
represents fractionation at protein level. Both approaches identified and quantified a number of 
medium to high abundant proteins in serum samples, and their relative levels between OSCC and 
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control subjects as revealed by both approaches were similar. However, because in-gel digestion was 
avoided, more proteins were identified and quantified with Approach 1 than Approach 2, especially the 
proteins of low abundance. In total, our analysis led to the quantitation of 381 serum proteins, 
including 219 ones that were quantified by both approaches (Figure 3B). 
Figure 2. Quantitative proteomic analysis of serum proteins from OSCC patients with 
Approach 1. In Approach 1, both OSCC and control protein samples were digested in 
solution, and the resulting peptides were labeled with iTRAQ tags, respectively. Afterwards, 
the labeled peptides were combined and fractionated with SCX at four different salt 
concentrations (50, 100, 250, and 500 mM sodium chloride). The filter-through and four 
SCX fractions were then analyzed by reversed phase LC with MS/MS. The number of 
proteins quantified in each SCX fractions is shown in (A); and their relative levels between 
OSCC and healthy control subjects are presented in (B); The total number of unique 
proteins quantified by this approach and their relative levels between OSCC and healthy 
control subjects are shown in (C). 
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survival rate for OSCC is approximately 30% to 40%. Such high morbidity rates can be attributed to 
poor diagnosis of OSCC. Methodological inconsistencies and lack of principles have led to subjective 
and unreliable results. As a consequence, OSCC is not diagnosed or treated until the late stages of the 
disease and has led to high reoccurrence rates. About one in four persons with oral cancer die because 
of delayed diagnosis or treatment. If OSCC is found early, before the cancer has metastasized, the  
five-year survival rate is nearly 90%. Recently more advanced detection methods have been developed 
for visual aid such as in vivo optical spectroscopy, tissue staining with toluidine blue, and exfoliated 
cytology using OralCDx brush biopsy (CDx Diagnostics, Suffern, NY, USA). Despite these advances, 
there has been little change in early OSCC detection and monitoring. The overall five-year survival 
rate for OSCC is among one of the lowest of all cancer types for the past few decades. 
Figure 3. Quantitative proteomic analysis of serum proteins from OSCC patients with 
Approach 2. In Approach 2, both OSCC and control protein samples were initially 
separated with SDS-PAGE. Highly abundant proteins within 50–70 kDa and around  
28 kDa were avoided, and the rest of proteins were excised for in-gel tryptic digestion (A); 
The resulting peptides were then labeled with iTRAQ tags, respectively, combined and 
fractionated with SCX. Afterwards, the SCX fractions were analyzed by reversed phase LC 
(RP-LC) with MS/MS. The number of proteins quantified by Approach 2 and their relative 
levels between OSCC and healthy control subjects are presented in (B); The pie chart 
shown in (C) indicates that most of the proteins are identified and quantified by both 
analytical approaches.  
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3. Experimental Procedures 
3.1. Patients and Serum Samples 
Serum samples were collected from oral cancer patients and healthy control subjects at the 
University of California-Los Angeles (UCLA) Medical Center as described previously [16].  
All participants provided consent according to the UCLA institutional review board (IRB) approval. 
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was 
approved by the UCLA IRB committee. The patients did not receive treatment in the form of 
chemotherapy, radiotherapy, surgery or alternative medicine prior to sample collection. The total 
protein concentration of serum samples was measured using the 2-D Quant Kit (GE Healthcare, 
Piscataway, NJ, USA). 
3.2. Depletion of High-Abundance Proteins in Serum Samples 
To identify protein candidates at differential levels between OSCC and healthy control subjects, we 
prepared equally pooled serum samples from healthy controls (n = 6) or OSCCs (n = 6), for 
quantitative proteomic analysis. These patient and control subjects were matched in terms of gender  
(p = 1.0) and ethnicity (p = 1.0). Acetonitrile (final concentration, 5%) was added to each sample as 
described previously to break down the binding of low-abundance proteins to serum albumin or 
immunoglobulins [15]. Afterwards, high-abundance proteins present in the pooled serum samples were 
selectively depleted with IgY-12 SC spin columns (Phenomenex, Torrance, CA, USA) according to 
the manufacturer’s manual. Afterwards, the protein concentrations of the depleted samples were 
measured and equal amount of proteins (either OSCC or healthy control) was used for iTRAQ labeling 
as described below. 
3.3. iTRAQ Labeling 
iTRAQ labeling was performed according to the manufacturer’s instruction manual (Applied 
Biosystems, Forster City, CA, USA). In brief, after depletion of high-abundance proteins, each pooled 
sample (100 µg proteins in total) was reduced with 5 mM tris-(2-carboxyethyl) phosphine (TCEP)  
at 60 °C for one hour and then incubated with 4 mM iodoactamide in the dark at room temperature  
for 30 min. Afterwards, the samples were digested with 2.5 µg sequencing grade trypsin (Promega, 
Madison, WI, USA) at 37 °C overnight and then reacted with iTRAQ-114 (control) and iTRAQ-117 
(OSCC), respectively. Finally, the labeled peptide samples were combined for 2-D LC separation and 
MS/MS analysis. 
3.4. SCX Fractionation and Reversed Phase (RP) LC with MS/MS 
The combined iTRAQ-114 and iTRAQ-117 labeled sample was first separated with Vivapure 
strong cation spin columns (Vivapure S MINI H, Sartorius, Germany) according to the manufacturer’s 
protocol. Prior to loading into the spin column, the labeled sample was diluted with water (1:8). The 
eluted fractions from the spin columns at four different salt concentrations (50, 100, 250, 500 mM 
sodium chloride) were then analyzed using nano-LC (Eksigent Technologies, Dublin, CA, USA) and 
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linear ion trap MS (LTQ XL, Thermo-Fisher Scientific, Waltham, MA, USA). Peptide separation was 
performed using the PepMap100 C18 column (3 µm, 100 A°, 75 µm I.D., 15-cm length, Dionex, 
Sunnyvale, CA, USA) with a 300-µm I.D. 3.5-mm-long C18 guard column (Dionex). Peptides  
were eluted using a linear gradient of 5%–95% LC buffer B (5% H2O, 95% ACN containing 0.1%  
formic acid) over 60 min, followed by isocratic elution at 95% buffer B for 15 min with a flow rate of 
400 nL/min across the capillary column. Electrospray (ESI) was performed at 2.0 kV using a PicoTip 
nanospray emitter (10-µm I.D., New Objective, Woburn, MA, USA).  
Peptides were selected for MS/MS using pulsed Q collision induced dissociation (PQD) operating 
mode with a normalized collision energy setting of 42%. The ion trap was operated in a data-dependent 
mode, with one MS survey scan (400–1800 m/z) followed by five MS/MS scans for the five most 
abundant precursor ions in the MS survey scan. The m/z values selected for MS/MS were dynamically 
excluded for 20 s. 
The obtained MS/MS spectra were searched against the NCBI non-redundant database using  
the Sequest search engine. Search parameters were set as follows: taxonomy, Homo sapiens;  
enzyme, semi-tryptic/tryptic; variable modifications, oxidation (M), phospho (ST), phospho (Y), 
carbamidomethyl (C), iTRAQ-4plex (K), iTRAQ-4plex (N-term), iTRAQ-4plex (Y); peptide mass 
tolerance, ±1.2 Da; fragment mass tolerance, ±0.6 Da; maximum missed cleavages, 1. Peptides with 
Xcorr > 2.0 (2+) or Xcorr > 2.5 (3+) were considered as significant match. Confident identification of 
a protein was based on two or more unique peptides and the false discovery rate was below 2%. 
Quantification of proteins was based on an average ratio of iTRAQ-labeled peptides from each protein. 
3.5. SDS-PAGE and In-Gel Tryptic Digestion 
Pooled serum samples (either OSCC or healthy control) were first precipitated with cold 10% TCA 
in acetone. The protein pellets were then dissolved in a buffer containing 7 M urea, 2 M thiourea,  
20 mM DTT, 1.2% CHAPS (w/v), 5% glycerol (v/v), 10% isopropanol (v/v), and 0.4% ASB-14 (w/v). 
Finally, the serum proteins (30 g, each pooled sample) were separated using 12% NuPAGE gels 
(Invitrogen, Carlsbad, CA, USA) and stained with Sypro Ruby (Bio-Rad, Fullerton, CA, USA). 
Selected protein bands (Figure 3A) were excised using the ProteomeWorks™ Spot Cutter (Bio-Rad). 
In-gel tryptic digestion of the proteins was then performed and the resulting peptides were extracted 
with 0.1% trifluoroacetic acid (TFA) in 50% acetonitrile. The peptides that resulted from each pooled 
sample were combined, vacuum dried, and labeled with iTRAQ 114 and 117 for control and OSCC 
samples, respectively. The labeled samples were finally combined and separated with the Vivapure 
strong cation spin columns (Vivapure S MINI H, Sartorius, Bohemia, NY, USA), as described above. 
The eluted fractions from the spin columns at four different salt concentrations (50, 100, 250,  
500 mM) were then analyzed using LC with MS/MS.  
4. Conclusions 
In summary, we have demonstrated and compared two analytical methods for quantification of 
serum proteins in patients with oral cancer based on iTRAQ labeling and LC-MS/MS analysis. These 
two methods represent fractionation at the peptide or protein level and are similarly effective for serum 
proteome analysis. As an effort to develop a possibly effective method for diagnosis or prognosis of 
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OSCC, researchers have utilized MS-based proteomics to identify body fluid (e.g., saliva and serum) 
biomarkers for disease detection/monitoring. We have previously demonstrated serum protein 
biomarkers may be used to differentiate OSCC patients with lymph node metastasis from those with 
primary disease [13]. A biomarker that reflects the status of lymph node metastasis is highly desirable 
to classify patients with OSCC for optimal treatment. Our present study provides compelling evidence 
that quantitative proteomic analysis of serum samples from OSCC patients may well lead to potential 
protein biomarkers to facilitate detection of OSCC. Once newly-discovered candidates are validated in 
large patient populations, they may be used to help detect OSCC or monitor patients (e.g., heavy 
smokers) who are at high risk for developing OSCC. 
Acknowledgments 
This study was supported in part by the PHS grant R21CA122806 and UC-TRDRP (S.H.). 
Author Contributions 
Yan Yang, Junwei Huang, Bahareh Rabii, and Ramin Rabii performed the study and data analysis. 
Shen Hu conceived of the study and design and drafted the manuscript. All authors read and approved 
the final manuscript.  
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics.  
CA Cancer J. Clin. 2011, 61, 69–90. 
2. Boring, C.C.; Squires, T.S.; Tong, T.; Montgomery, S. Cancer statistics, 1994. CA Cancer J. Clin. 
1994, 44, 7–26. 
3. Day, G.L.; Blot, W.J. Second primary tumors in patients with oral cancer. Cancer 1992, 70, 14–19. 
4. Lippman, S.M.; Hong, W.K. Molecular markers of the risk of oral cancer. N. Engl. J. Med. 2001, 
344, 1323–1326. 
5. Park, B.J.; Chiosea, S.I.; Grandis, J.R. Molecular changes in the multistage pathogenesis of head 
and neck cancer. Cancer Biomark. 2011, 9, 325–339. 
6. Hoffmann, J.; Munz, A.; Krimmel, M.; Alfter, G. Intraoperative and postoperative kinetics of 
serum tumor markers in patients with oral carcinoma. J. Oral Maxillofac. Surg. 1998, 56, 1390–1393. 
7. Krimmel, M.; Hoffmann, J.; Krimmel, C.; Cornelius, C.; Schwenzer, N. Relevance of SCC-Ag, 
CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer. J. Craniomaxillofac. Surg. 
1998, 26, 243–248. 
8. Kurokawa, H.; Yamashita, Y.; Tokudome, S.; Kajiyama, M. Combination assay for tumor 
markers in oral squamous cell carcinoma. J. Oral Maxillofac. Surg. 1997, 55, 964–966. 
Int. J. Mol. Sci. 2014, 15 14395 
 
 
9. Kurokawa, H.; Tsuru, S.; Okada, M.; Nakamura, T.; Kajiyama, M. Evaluation of tumor markers 
in patients with squamous cell carcinoma in the oral cavity. Int. J. Oral Maxillofac. Surg. 1993, 
22, 35–38. 
10. Brady, G.; O’Regan, E.; Miller, I.; Ogungbowale, A.; Kapas, S.; Crean, S.J. Serum levels of 
insulin-like growth factors (IGFs) and their binding proteins (IGFBPs), -1, -2, -3, in oral cancer. 
Int. J. Oral Maxillofac. Surg. 2007, 36, 259–262. 
11. Nagler, R.; Barak, M.; Peled, M.; Ben-Aryeh, H.; Filatov, M.; Laufer, D. Early diagnosis and 
treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell 
carcinoma. Cancer 1999, 85, 1018–1025. 
12. Ross, P.L.; Huang, Y.N.; Marchese, J.N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; 
Pillai, S.; Dey, S.; Daniels, S.; et al. Multiplexed protein quantitation in Saccharomyces cerevisiae 
using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154–1169. 
13. Chai, D.; Zhang, L.; Yang, Y.; Su, T.; Charugundla, P.; Ai, J.A.; Messadi, D.; Hu, S. Serum 
protein biomarkers for lymph-node metastasis in oral cancer. Head Neck 2014, under revision. 
14. Misuno, K.; Liu, X.; Feng, S.; Hu, S. Quantitative proteomic analysis of sphere-forming, oral 
cancer stem-like cells. Stem Cell Res. Ther. 2013, 4, 156. 
15. Huang, H.-L.; Stasyk, T.; Morandell, S.; Mogg, M.; Schreiber, M.; Feuerstein, I.; Huck, C.W.; 
Stecher, G.; Bonn, G.K.; Huber, L.A. Enrichment of low-abundant serum proteins by 
albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions. 
Electrophoresis 2005, 26, 2843–2849. 
16. Li, Y.; Elashoff, D.; Oh, M.; Sinha, U.; St John, M.A.R.; Zhou, X.; Abemayor, E.; Wong, D.T. 
Serum circulating human mRNA profiling and its utility for oral cancer detection. J. Clin. Oncol. 
2006, 24, 1754–1760. 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
